Presented as part of the 2018 Koch Institute Summer Symposium: Breakthrough Cancer Nanotechnologies, this multidisciplinary panel discussion explores the impact of nanomedicine on the future of cancer care. The panel was moderated by Bloomberg Biotech Reporter Rebecca Spalding and features insight from:
Noubar Afeyan, PhD
Founder and CEO, Flagship Pioneering
Michelle S. Bradbury, MD, PhD
Co-Director, MSK-Cornell Center for Translation of Cancer Nanomedicines
Director, Intraoperative Imaging Program
Member, Molecular Pharmacology Program, Sloan Kettering Institute
Attending, Radiology, Memorial Sloan Kettering Cancer Center
Professor, Gerstner Sloan Kettering Graduate School of Biomedical Sciences & Weill Medical College of Cornell University
Paula Hammond, PhD
Head, Department of Chemical Engineering, MIT
David H. Koch Professor of Engineering, MIT
Member, Koch Institute, MIT
Robert Langer, ScD
David H. Koch Institute Professor
Member, Koch Institute, MIT
John Maraganore, PhD
CEO and Director, Alnylam
Cristianne Rijcken, PhD
Founder and Chief Scientific Officer, Cristal Therapeutics
